Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

Philip Norman worked as an illustrator, author and artist before making his first forays into engineering and mechanics.

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

The global automotive cybersecurity market is growing rapidly, expected to be valued at around US$ 4,050.3 million in 2026 ...

TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapse "Together with the updated ...

Hewlett Packard Enterprise Co. struggled to interest some investors and other tech companies in buying assets that the US ...

Conflict does not begin with violence. It begins with perception. Before the first shot is fired, before the first act of ...

Researchers have optimized a headspace sorptive extraction (HSSE) method coupled with gas chromatography-mass spectrometry ...

The Ministry of Health advises that, through laboratory testing, Yellow Fever has been confirmed in a deceased Red Howler ...

Abstract: Compared with the single-vector-based model predictive control (MPC) technique, the multiple-vector-based MPC technique gains interests in improving the total harmonic distortion (THD) of ...